详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

China Glaucoma Treatment Pattern Study I-Primary Angle-Closure Glaucoma: protocol for a multicentre, retrospective, observational study

6| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Ophthalmology, Fujian Medical University, Fuzhou, Fujian, China. [2]Department of Ophthalmology, Wenzhou Medical University Eye Hospital, Wenzhou, Zhejiang, China. [3]Department of Ophthalmology, Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China. [4]Department of Ophthalmology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. [5]Department of Ophthalmology, Jilin University Second Hospital, Changchun, Jilin, China. [6]Department of Ophthalmology, Jilin Province Hospital of Chinese Medicine, Changchun, Jilin, China. [7]Department of Ophthalmology, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital, Shanghai, Shanghai, China. [8]Eye Center, Xiangya Hospital Central South University, Changsha, Hunan, China. [9]Hunan Key Laboratory of Ophthalmology, Changsha, Hunan, China. [10]Hunan Provincial People's Hospital, Changsha, Hunan, China. [11]Sichuan University West China Hospital, Chengdu, Sichuan, China. [12]Department of Ophthalmology, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China. [13]Department of Ophthalmology, Lanzhou University Second Hospital, Lanzhou, Gansu, China. [14]Department of Ophthalmology, Gansu Provincial People's Hospital, Lanzhou, Gansu, China. [15]Department of Ophthalmology, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China. [16]Wenzhou Medical University Eye Hospital, Wenzhou, Zhejiang, China yuanboliang@wmu.edu.cn. [17]Sichuan University West China Hospital, Wuhou, Sichuan, China. [18]State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China. [19]Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia.

出处：

DOI：

ISSN：

摘要：

Primary angle-closure glaucoma (PACG) is a leading cause of irreversible blindness globally, and the number of patients with PACG rises every year. Yet, there is a lack of knowledge about the clinical characteristics, therapeutic options and profile of patients with PACG in China. Hence, we design the China Glaucoma Treatment Pattern Study Ⅰ-Primary Angle-Closure Glaucoma (Ch-GTPⅠ). The objective of this paper is to describe the design and methodology of Ch-GTP. The aim of this study is to characterise the profile and trend associated with initial PACG treatment for the last 10 years in China.Ch-GTPⅠ is a national multicentre retrospective observational study that will randomly sample from 50 hospitals throughout China. Over 7000 patient records hospitalised for initial PACG treatment from 2011 to 2020 will be selected randomly. The data from electronic medical records will be uploaded to an encrypted online platform that will receive and collate data from all collaborating hospitals. Data abstraction and monitoring will be performed in a standardised manner by trained statisticians to ensure consistency. Systematic data cleaning will also be conducted by statisticians to ensure data integrity before final data storage. The outcomes will include four broad categories: (1) demographics, (2) clinical characteristics, (3) therapeutic strategies and procedures and (4) early outcomes at discharge. The demographic characteristics and early outcomes will be summarised using descriptive statistics. Comparative analyses of characteristics and treatment pattern changing trends for different regions and years will be used to test for significant differences (t-test or Mann-Whitney U test).The collaborating hospitals obtained local approval based on a standard ethics application from internal ethics committees or acknowledged an existent ethics approval of the leading institution with approval from internal ethics committees. Due to the retrospective nature, written informed consent from patients was waived by the ethics committee. The results will be published in academic journals and presented at national and international academic conferences.ChiCTR2100054643.© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区医学：内科

最新[2025]版：

大类 | 4 区医学

小类 | 4 区医学：内科

JCR分区：

出版当年[2021]版：

Q2 MEDICINE, GENERAL & INTERNAL

最新[2023]版：

Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 2.4 最新[2023版] 2.7 最新五年平均 3.007 出版当年[2021版] 3.587 出版当年五年平均 2.692 出版前一年[2020版] 2.9 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Ophthalmology, Fujian Medical University, Fuzhou, Fujian, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：